KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Operations (2016 - 2025)

Pacific Biosciences Of California has reported Cash from Operations over the past 16 years, most recently at 19069000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 19069000.0 for Q4 2025, up 37.78% from a year ago — trailing twelve months through Dec 2025 was 111209000.0 (up 46.03% YoY), and the annual figure for FY2025 was 111209000.0, up 46.03%.
  • Cash from Operations for Q4 2025 was 19069000.0 at Pacific Biosciences Of California, down from 18707000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for PACB hit a ceiling of 15712000.0 in Q2 2021 and a floor of 94691000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 45463000.0 (2024), compared with a mean of 47903947.37.
  • Biggest five-year swings in Cash from Operations: crashed 285.46% in 2022 and later soared 58.85% in 2025.
  • Pacific Biosciences Of California's Cash from Operations stood at 31708000.0 in 2021, then crashed by 91.01% to 60566000.0 in 2022, then increased by 4.96% to 57560000.0 in 2023, then surged by 46.75% to 30650000.0 in 2024, then surged by 37.78% to 19069000.0 in 2025.
  • The last three reported values for Cash from Operations were 19069000.0 (Q4 2025), 18707000.0 (Q3 2025), and 29377000.0 (Q2 2025) per Business Quant data.